# EDGAR Filing Document

**Accession Number:** 0001360214
**File Stem:** 0001641172-25-015665
**Filing Date:** 2025-6
**Character Count:** 7148
**Document Hash:** 2cbec81a0035d4ae62d0489525c80758
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-015665.hdr.sgml**: 20250620

**ACCESSION NUMBER**: 0001641172-25-015665

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20250618

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20250620

**DATE AS OF CHANGE**: 20250620

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** HARROW, INC.
- **CENTRAL INDEX KEY:** 0001360214
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 450567010
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35814
- **FILM NUMBER:** 251058922

**BUSINESS ADDRESS:**
- **STREET 1:** 1A BURTON HILLS BLVD
- **STREET 2:** SUITE 200
- **CITY:** NASHVILLE
- **STATE:** TN
- **BUSINESS PHONE:** 615.733.4731

**MAIL ADDRESS:**
- **STREET 1:** 1A BURTON HILLS BLVD
- **STREET 2:** SUITE 200
- **CITY:** NASHVILLE
- **STATE:** TN

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** HARROW HEALTH, INC.
- **DATE OF NAME CHANGE:** 20181228

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Imprimis Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20120301

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TRANSDEL PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 20070912

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 18, 2025**

**HARROW, INC.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-35814** | **45-0567010** |
| (State or other jurisdiction<br> of incorporation) | (Commission<br> File Number) | (IRS Employer<br> Identification No.) |

---

---

| | |
|:---|:---|
| **1A Burton Hills Blvd., Suite 200** |  |
| **Nashville, Tennessee** | **37215** |
| (Address of principal executive offices) | (Zip Code) |

---

Registrant's telephone number, including area code: **(615) 733-4730**

**Not Applicable**

(Former Name or Former Address, if Changed Since Last Report)

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of exchange on which registered |
| Common Stock, $0.001 par value per share | HROW | The Nasdaq Stock Market LLC |
| 8.625% Senior Notes due 2026 | HROWL | The Nasdaq Stock Market LLC |
| 11.875% Senior Notes due 2027 | HROWM | The Nasdaq Stock Market LLC |

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Act of 1934: Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

On June 18, 2025, the Company held its 2025 Annual Meeting of Stockholders (the "Annual Meeting"). The number of shares of common stock entitled to vote at the Annual Meeting was 36,685,171. The number of shares of common stock present or represented by valid proxy at the Annual Meeting was 31,271,714. All matters submitted to a binding vote of stockholders at the Annual Meeting were approved. The number of votes cast for and against, and the number of abstentions and broker non-votes with respect to the matters voted upon at the Annual Meeting, are set forth below:

*Proposal 1: Election of Directors*

Stockholders voted to elect to the Board of Directors the four (4) director nominees named in the Company's proxy statement to serve until the 2026 annual meeting of stockholders or until their successors are duly elected and qualified. The results of the voting were:

---

| | | | |
|:---|:---|:---|:---|
| **Directors** | **For** | **Withheld** | **Broker Non-Vote** |
| Mark L. Baum | 23643847 | 272563 | 7355304 |
| Adrienne L. Graves | 23200214 | 716196 | 7355304 |
| Lauren P. Silvernail | 23624033 | 292377 | 7355304 |
| Perry J. Sternberg | 23616257 | 300153 | 7355304 |

---

*Proposal 2: Approval of the Harrow, Inc. 2025 Incentive Stock and Awards Plan*

 

Stockholders voted to approve the Harrow, Inc. 2025 Incentive Stock and Awards Plan. The results of the voting were:

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstain** | **Broker Non-Vote** |
| 21700605 | 1773539 | 442266 | 7355304 |

---

*Proposal 3: Ratification of Auditors*

Stockholders ratified the selection of Crowe LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. The results of the voting were:

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstain** | **Broker Non-Vote** |
| 31229548 | 23282 | 18884 | **-** |

---

*Proposal 4: To approve on a non-binding, advisory basis, the compensation of the Company's named executive officers.*

Stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers. The results of the voting were:

---

| | | | |
|:---|:---|:---|:---|
| **For** | **Against** | **Abstain** | **Broker Non-Vote** |
| 22496427 | 971206 | 448777 | 7355304 |

---

 

*Proposal 5: To approve on a non-binding, advisory basis, the frequency of a stockholder advisory vote on the compensation of the Company's named executive officers.*

Stockholders approved, on a non-binding, advisory basis, a frequency of one year for a stockholder advisory vote on the compensation of the Company's named executive officers. The results of the voting were:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **One Year** | **Two Years** | **Three Years** | **Abstain** | **Broker Non-Vote** |
| 20415407 | 7346 | 2868210 | 625447 | 7355304 |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **HARROW, INC.** | **HARROW, INC.** |
| Dated: June 20, 2025 | By: | */s/ Andrew R. Boll* |
|  |  | Andrew R. Boll |
|  |  | Chief Financial Officer |

---